SCHEMBL9748313

SCHEMBL9748313

CCNc1ccc(N)cc1S(=O)(=O)NS(=O)(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.42
▸ MAPT P10636 3/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ NSD2 O96028 1/20 0.42
▸ APEX1 P27695 1/20 0.42
▸ APOBEC3A P31941 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ CASP6 P55212 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ HTR6 P50406 2/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ NAT1 P18440 1/20 0.39
▸ METAP2 P50579 2/20 0.39
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9750234 0.83 L3MBTL1 (0.39) GAAMAPTKDM4EL3MBTL1POLB
SCHEMBL9749499 0.80 CRHBP (0.52) GAAMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL9083398 0.75 RAPGEF4 (0.59) GAAMAPTKDM4EL3MBTL1POLB
SCHEMBL10889640 0.72 CA12 (0.39) GAAMAPTKDM4EL3MBTL1POLB
SCHEMBL8564462 0.72 KMT2A (0.66) GAAMAPTALDH1A1TDP1HTR6
SCHEMBL10891838 0.71 SIGMAR1 (0.47) ALDH1A1KMT2AGFERLMNA
Monoethanolamine SCHEMBL14989152 0.71 ALDH1A1 (0.40) GAAMAPTKDM4EL3MBTL1POLB
SCHEMBL5673665 0.71 POLB (0.69) POLBALDH1A1TDP1HTR6KEAP1
SCHEMBL10894158 0.70 GAA (0.50) GAAL3MBTL1POLBALDH1A1RECQL
SCHEMBL10889586 0.70 CA12 (0.43) L3MBTL1POLBALDH1A1RECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9872822-B2 Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition L'OREAL (FR) 2018-01-23 — — US disclosed
US-9872822-B2 Process for dyeing in the presence of oxidation bases comprising at least one sulfonic, sulfonamide, sulfone, amid or acid group and a metal catalyst, device and ready-to-use composition L'OREAL (FR) 2018-01-23 — — US disclosed
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION L'OREAL (FR) 2016-05-26 — — US disclosed
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION L'OREAL (FR) 2016-05-26 — — US disclosed
EP-0205079-B1 ACID DISULFIMIDE TRIPHENODIOXAZINE DYES BAYER AG (DE) 1992-01-22 — — EP disclosed
EP-0205079-A2 Acid disulfimide triphenodioxazine dyes BAYER AG (DE) 1986-12-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160143826-A1 PROCESS FOR DYEING IN THE PRESENCE OF OXIDATION BASES COMPRISING AT LEAST ONE SULFONIC, SULFONAMIDE, SULFONE, AMID OR ACID GROUP AND A METAL CATALYST, DEVICE AND READY-TO-USE COMPOSITION KRT18, ARSA, SQOR GAA 872/4885MAPT 2197/4885KDM4E 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback